STAMPEDEing metastatic prostate cancer: CHAARTing the LATITUDEs
Aditya Prakash Sharma, Ravimohan S Mavuduru, Girdhar Singh Bora, Sudheer K Devana, Shrawan K Singh, Arup K MandalIndian Journal of Urology 2018 34(3):180-184With the emergence of recent landmark trials, the treatment for hormone-sensitive metastatic prostate cancer (hsMPC) is changing from androgen deprivation therapy (ADT) alone to combination therapy. Both, docetaxel chemotherapy and abiraterone in addition to ADT have been extensively studied in well-conducted randomized controlled trials and were shown to improve outcomes. However, this paradigm shift in the treatment has also raised some queries. This mini review reflects upon the four landmark trials and tries to provide some perspective about the decision-making process for the patients with hsMPC.
Source: Indian Journal of Urology - Category: Urology & Nephrology Authors: Aditya Prakash Sharma Ravimohan S Mavuduru Girdhar Singh Bora Sudheer K Devana Shrawan K Singh Arup K Mandal Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Docetaxel | Hormones | India Health | Prostate Cancer | Taxotere | Urology & Nephrology